# Friedreich Ataxia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/friedreich-ataxia

> 6 upcoming FDA catalysts in Friedreich Ataxia: nomlabofusp (LRMR) on January 2027 (primary completion); nomlabofusp (LRMR) on Jan to Apr 2027 (topline data readout); SKYCLARYS® (omaveloxolone, BIIB) on Nov 2027 to Feb 2028 (topline data readout); SKYCLARYS® (omaveloxolone, BIIB) on November 2027 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 2027 | [Nomlabofusp primary completion](https://sec-api.dev/pdufa/nomlabofusp) | LRMR | Friedreich Ataxia | scheduled | "NCT06447025 (An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Larimar Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06447025)) |
| Jan to Apr 2027 | [Nomlabofusp topline data readout](https://sec-api.dev/pdufa/nomlabofusp) | LRMR | Friedreich Ataxia | scheduled | "NCT06447025 (An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Larimar Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06447025)) |
| Nov 2027 to Feb 2028 | [SKYCLARYS® (omaveloxolone) topline data readout](https://sec-api.dev/pdufa/omaveloxolone) | BIIB | Friedreich Ataxia | scheduled | "NCT06953583 (A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06953583)) |
| November 2027 | [SKYCLARYS® (omaveloxolone) primary completion](https://sec-api.dev/pdufa/omaveloxolone) | BIIB | Friedreich Ataxia | scheduled | "NCT06953583 (A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06953583)) |
| Dec 2027 to Mar 2028 | [Vatiquinone topline data readout](https://sec-api.dev/pdufa/vatiquinone) | PTCT | Friedreich Ataxia | scheduled | "NCT05515536 (A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor PTC Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05515536)) |
| December 2027 | [Vatiquinone primary completion](https://sec-api.dev/pdufa/vatiquinone) | PTCT | Friedreich Ataxia | scheduled | "NCT05515536 (A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor PTC Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05515536)) |

## Drugs

- [Nomlabofusp](https://sec-api.dev/pdufa/nomlabofusp) (LRMR)
- [SKYCLARYS® (omaveloxolone)](https://sec-api.dev/pdufa/omaveloxolone) (BIIB)
- [Vatiquinone](https://sec-api.dev/pdufa/vatiquinone) (PTCT)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/friedreich-ataxia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Friedreich Ataxia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/friedreich-ataxia

```bibtex
@misc{secapidev_indications_friedreich_ataxia_20261116,
  title        = {Friedreich Ataxia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/friedreich-ataxia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_friedreich_ataxia_20261116","title":"Friedreich Ataxia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/friedreich-ataxia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
